- Home
- LSTA vs INKT Comparison
LSTA vs INKT Comparison
Compare LSTA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | INKT |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 45.2M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSTA | INKT |
|---|---|---|
| Price | $5.01 | $11.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $15.00 | ★ $35.00 |
| AVG Volume (30 Days) | 54.8K | ★ 175.6K |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $6.66 |
| 52 Week High | $5.07 | $76.00 |
Technical Indicators
Market Signals| Indicator | LSTA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 68.19 | 54.11 |
| Support Level | $5.00 | $6.80 |
| Resistance Level | $5.07 | $12.64 |
| Average True Range (ATR) | 0.02 | 0.86 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 20.00 | 69.08 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.